Cite
HARVARD Citation
Barajas, R. et al. (2022). [18F]-fluoromisonidazole (FMISO) PET/MRI hypoxic fraction distinguishes neuroinflammatory pseudoprogression from recurrent glioblastoma in patients treated with pembrolizumab. Neuro-oncology practice. 9 (3), pp. 246-250. [Online].